Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.

Next Previous
Search
Trial Profile

Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRM 197 (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 13 Apr 2016 Status changed from suspended to discontinued.
    • 07 Dec 2015 Status changed from recruiting to suspended, as reported by University Hospital Medical Information Network - Japan.
    • 19 Mar 2015 Status changed from not yet recruiting to recruiting, according to University Hospital Medical Information Network - Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top